How did GSK’s Nuvalent acquisition lead to its Jideytro lung cancer approval?

GSK’s $10.6 billion purchase of Nuvalent brought in the asset that became Jideytro, which has now earned FDA approval as GSK’s first lung cancer treatment. The swift transition from acquisition to approval highlights effective integration of external R&D and marks a key milestone in GSK’s shift toward an oncology-focused growth strategy.